Merck: COVID-19 oral antiviral drug reduces risk of death
The pharma firm reports molnupiravir was shown to cut risk of hospitalization or death by 50% compared to placebos in a positive interim Phase III analysis.
Stay updated with breaking news from Phase 3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The pharma firm reports molnupiravir was shown to cut risk of hospitalization or death by 50% compared to placebos in a positive interim Phase III analysis.
That's -- it's not usually done that way, and dr. offit and others say because president biden set a date, that means we now have to rush this, and they do feel rushed, many of them. >> okay, elizabeth cohen, thank you very much for explaining everything that's happening in that meeting right now. let's bring in our medical experts, dr. steven thomas, a coordinating principal investigator for pfizer's phase 3 trial, he also helped lead its global vaccine trial. and dr. chris pernell volunteered in a moderna trial. dr. thomas, let's assume that the fda says yes to boosters and then the cdc says...
Frontier Applied Sciences (FAS) has received independent validation of its proprietary...
Two more COVID-19 relief measures for Fiji National Provident Fund members will open on Monday 16th August, 2021. The two relief withdrawals are: i. Phase 3, for members who are...
The company will soon make Phase III trials data public